Климактерический синдром
Литература
1. Сметник В.П., Кулаков В.И. Руководство по климактерии. — М. :
Мед. информ. агентство,2001.
2. Анкирская А.С. Бактериальный вагиноз // Акуш. и гин. — 1995. —
№ 6. — C. 13–16.
3. Judd H.L., Fournet N. Changes of ovarian function with aging // Exp.
Gerontol. — 1994. — Vol. 29. — P. 285.
4. Judd H.L., Yen S.S.C. Serum androstenedione and testosterone levels
during the menstrual cycle // J. Clin. Endocrinol. Metab. — 1973. — Vol.
36. — P. 475.
5. Horton Tait J.F. Androstenedione production and interconversion rates
measured in peripheral blood and studies on the possible site of its conversion
to testosterone // Ibid. — 1966. — Vol. 45. — P. 301.
6. Speroff L., Glass R.H., Kase N.G. (eds). Clinical Gynecologic
Endocrinology and Infertility. — 5th ed. — Baltimore : Williams and Wilkins,
1994.
7. Adashi E.Y. The climacteric ovary: A viable endocrine organ // Semin.
Reprod. Endocrinol. — 1991. — Vol. 9. — P. 200.
8. Bardin C.W., Lipsett M.B. Testosterone and androstenedione blood
production rates in normal women and women with idiopathic hirsutism or
polycystic ovaries // J. Clin. Invest. — 1967. — Vol. 46. — P. 891.
9. Origin of serum estradiol in postmenopausal women / H.L Judd., I.M.
Shamonki, A.M. Freemar et al. // Obstet. Gynecol. — 1982. — Vol. 59. —
P. 680.
10. Mishell D.R., Davajan V., Lobo R.A. (eds). Infertility, Contraception and
Reproductive Endocrinology. — Boston : Blackwell Scientific, 1991.
11. Greenwald G.S. How does daily treatment with human chorionic gonadotropin
induce superovulation in the cyclic hamster? // Biol. Reprod. — 1993. —
Vol. 48. — P. 133.
12. Administration of an aromatase inhibitor during the late follicular
phase of gonadotropin-treated cycles in rhesus monkeys: Effects on follicle
developments, oocyte maturation and subsequent luteal function / M.B.
Zelinski-Wooten, D.L. Hess, W.L. Baughman et al. // J. Clin. Endocrinol.
Metab. — 1993. — Vol. 76. — P. 988.
13. Daniel S.A.J., Armstrong S.T. Androgens in the ovarian micro environment //
Semin. Reprod. Endocrinol. — 1986. — Vol. 4. — P. 89.
14. McEwen B.S. Gonadal hormone receptors on the developing and adult
brain: Relationship to the regulatory phenotype // Fetal Neuroendocrinology /
eds F. Ellerdorf et al. — Ithaca : Perinatology Press, 1984. — P. 149.
15. Identification of androgen receptors in normal human osteoblast-like
cells / D.S. Colvard, E.E. Eriksen, P.E. Keeting et al. // Proc. Natl Acad.
Sci. USA. — 1989. — Vol. 86. — P. 854.
16. Hutchinson K.A. Androgens and sexuality // Am. J. Med. — 1995. — Vol.
98. — P. 111S.
17. Money J., Erhardt A.A. (eds). Man and Woman, Boy and Girl: The
Differentiation and Dimorphism of Gender Identity from Conception to
Maturity. — Baltimore : Johns Hopkins University Press, 1972.
18. Sherwin B.B. Changes in sexual behavior as a function of plasma sex steroid
levels in postmenopausal women // Maturitas. — 1985. — Vol. 7. — P. 225.
19. Sherwin B.B., Gelfand M.M., Brender W. Androgen enhances
sexual motivation in females: A prospective, crossover study of sex steroid
administration in the surgical menopause // Psychosom. Med. — 1985. — Vol.
47. — P. 339.
20. Effect of combined implants of oestradiol and testosterone on libido in
postmenopausal women / H. Burger, J. Hailes, J. Nelson et al. // Br. Med.
J. (Clin. Res.). — 1987. — Vol. 294. — P. 936.
21. The effects of subcutaneous hormone implants during climacteric /
L. Cardozo, D.M. Gibb, S.M. Tuck et al. // Maturitas. — 1984. — Vol. 5. —
P. 177.
22. Androgen and estrogen dynamics in women with vertebral crush fractures /
C. Longcope, R.S. Baker, S.C. Hui et al. // Ibid. — Vol. 6. — P. 309.
23. Sex steroids and bone density in premenopausal and perimenopausal
women / K.K. Steinberg, L.W. Freni-Titulaer, E.G. DePuey et al. // J. Clin.
Endocrinol. Metab. — 1989. — Vol. 69. — P. 533.
24. Sex steroids, bone mass, and bone loss / C. Slemenda, C. Longcope,
M. Peacock et al. // J. Clin. Invest. — 1996. — Vol. 97. — P. 14.
25. Judd H.L., Judd G.E., Lucas W.E., Yen S.S. Endocrine function of
the postmenopausal ovary: Concentrations of androgens and estrogens in
ovarian and peripheral vein blood // J. Clin. Endocrinol. Metab. — 1974. — Vol.
39. — P. 1020.
26. Adashi E.Y. The climacteric ovary as a functional gonadotropin-driven
androgen producing gland // Fertil. Steril. — 1994. — Vol. 62. — P. 20.
27. Judd H.L., Lucas W.E., Yen S.S. Effect of oophorectomy on circulating
testosterone and androstenedione levels in patients with endometrial cancer //
Am. J. Obstet. Gynecol. — 1974. — Vol. 118. — P. 793.
28. Hysterectomy, oophorectomy, and endogenous sex hormone levels in
older women: the Rancho Bernardo Study / G.A. Laughlin, E. Barrett-Connor,
D. Kritz-Silverstein et al. // J. Clin. Endocrinol. Metab. — 2000. — Vol.
85. — P. 645.
29. Gonadotropin binding sites in human postmenopausal ovaries / J.J.
Peluso, R.W. Steger, S. Jaszcza et al. // Fertil. Steril. — 1976. — Vol. 27. —
P. 789.
30. Binding sites for gonadotropins in human postmenopausal ovaries /
R. Nakano, K. Shimo, M. Yamoto et al. // Obstet. Gynecol. — 1989. — Vol.
73. — P. 196.
31. Steroid production and responsiveness to gonadotropin in isolate stromal
tissue of human postmenopausal ovaries / B.L. Dennefors, P.O. Janson,
F. Knutson et al. // Am. J. Obstet. Gynecol. — 1980. — Vol. 136. —
P. 997.
32. Hilus cells from human postmenopausal ovaries: gonadotrophin
sensitivity, steroid and cyclic AMP production / B.L. Dennefors, P.O. Janson,
L. Hamburger et al. // Acta Obstet. Gynecol. Scand. — 1982. — Vol. 61. —
P. 413.
33. Vermeulen A. The hormonal activity of the postmenopausal ovary //
J. Clin. Endocrinol. Metab. — 1976. — Vol. 42. — P. 247.
34. Effect of chorionic gonadotropin on postmenopausal women / A. Poliak,
G.E.S. Jones, B. Goldberg et al. // Am. J. Obstet. Gynecol. — 1971. — Vol.
109. — P. 555.
35. Greenblatt R.B., Colle M.L., Mahesh V.B. Ovarian and adrenal steroid
production in the postmenopausal women // Obstet. Gynecol. — 1976. — Vol.
47. — P. 383.
36. Testosterone enhances estradiol’s effect on postmenopausal bone density
and sexuality / S.R. Davis, P. McCloud, B.J.G. Strauss et al. // Maturitas. —
1995. — Vol. 21. — P. 227.
37. Differential effects of oral estrogen versus oral estrogen-androgen
replacement therapy on body composition in postmenopausal women /
A.S. Dobs, T. Nguyen, C. Pace et al. // J. Clin. Endocrinol. Metab. — 2002. —
Vol. 87. — P. 1509.
38. Effects of estrogen, androgen and progestin on sexual psychophysiology
and behavior in postmenopausal women / L.S. Myers, J. Dixen, D. Morrissette
et al. // Ibid. — 1990. — Vol. 70. — P. 1124.
39. Sexuality, hormones and the menopausal transition / L. Dennerstein,
E.C. Dudley, J.L. Hopper et al. // Maturitas. — 1997. — Vol. 26. — P. 83.
40. Transdermal testosterone treatment in women with impaired sexual
function after oophorectomy / J.L. Shifren, G.D. Braunstein, J.A. Simon et
al. // N. Engl. J. Med. — 2000. — Vol. 343. — P. 682.
41. Effect of oestrogen and testosterone implants on psychological disorders in
the climacteric / J.C. Montgomery, L. Appleby, M. Brincat et al. // Lancet. —
1987. — Vol. 1. — P. 297.
42. Sherwin B.B. Affective changes with oestrogen and androgen replacement
therapy in surgically menopausal women // J. Affect. Disord. — 1988. — Vol.
14. — P. 177.
43. Sherwin B.B., Gelfand M. Differential symptom response to parenteral
oestrogen and/or androgen administration in the surgical menopause // Am.
J. Obstet. Gynecol. — 1985. — Vol. 151. — P. 153.
44. Comparison of the effects of estrogen alone and estrogen plus androgen
on the biochemical markers of bone formation and resorption in postmenopausal
women / L.G. Raisz, B. Witta, A. Artis et al. // J. Clin. Endocrinol. Metab. —
1996. — Vol. 81. — P. 37.
45. Effects of nandrolone decanoate and antiresorptive therapy on vertebral
density in osteoporotic postmenopausal women / A.G. Need, M. Horowitz,
A. Bridges et al. // Arch. Intern. Med. — 1989. — Vol. 149. — P. 57.
46. Comparison of calcium, calcitriol, ovarian hormones and nandrolone
in the treatment of osteoporosis / A.G. Need, B.E. Chatterton, C.J. Walker
et al. // Maturitas. — 1986. — Vol. 8. — P. 275.
47. Effect of nandrolone decanoate and l-alpha hydroxy-calciferol on patients
with vertebral osteoporotic collapse: A double-blind clinical trial / G.P. Lyritis,
C. Androulakis, B. Magiasis et al. // Bone Miner. — 1994. — Vol. 27. — P. 209.
48. Stanozolol in postmenopausal osteoporosis: therapeutic efficacy and
possible mechanisms of action / C.H. Chesnut 3rd, J.L. Ivey, H.E. Gruber et
al. // Metabolism. — 1983. — Vol. 32. — P. 571.
49. Increase in bone mass after one year of percutaneous oestradiol and
testosterone implants in postmenopausal women who have previously received
long-term oral oestrogens / M. Savvas, J.W. Studd, S. Norman et al. //
Br. J. Obstet. Gynaecol. — 1992. — Vol. 99. — P. 757.
50. Comparison of oral estrogens and estrogen plus androgen on bone
mineral density, menopausal symptoms and lipid-lipoprotein profiles in surgical
menopause / N.B. Watts, M. Notelovitz, M.C. Timmons et al. // Obstet.
Gynecol. — 1995. — Vol. 85. — P. 529.
51. Short and long-term effects of estrogen and synthetic anabolic hormone
in postmenopausal osteoporosis / B.L. Riggs, J. Jowsey, R.S. Goldsmith et al. //
J. Clin. Invest. — 1972. — Vol. 51. — P. 1659.
52. The effect of circulating dehydroepiandrosterone supplementation
to symptomatic perimenopausal women on serum endocrine profiles, lipid
parameters, and health-related quality of life / K.T. Barnhart, E. Freeman, J.A.
Grisso et al. // J. Clin. Endocrinol. Metab. — 1999. — Vol. 84. — P. 3896.
53. Lipoprotein lipid concentrations and cardiovascular risk in women with
polycystic ovary syndrome / R.A. Wild, P.C. Painter, P.B. Couson et al. //
Ibid. — 1985. — Vol. 61. — P. 946.
54. Evidence of heterogeneous mechanisms in lipoprotein lipid alterations
in hyperandrogenic women / R.A. Wild, M. Bartholomew, D. ApplebaumBowden et al. // Am. J. Obstet. Gynecol. — 1990. — Vol. 163. — P. 1998.
55. The relation of endogenous sex steroid hormone concentrations to serum
lipid and lipoprotein levels in postmenopausal women / J.A. Cauley, J.P. Gutai,
L.H. Kuller et al. // Am. J. Epidemiol. — 1990. — Vol. 123. — P. 884.
56. Relationship of plasma HDL-cholesterol to testosterone, estradiol,
and sex hormone-binding globulin levels in men and women / J. Semmens,
I. Rouse, L.J. Beilin et al. // Metabolism. –1983. — Vol. 32. — P. 428.
57. Effects of conjugated equine estrogen with and without three different
progestins on lipoproteins; high density lipoprotein subtractions, and
apolipoprotein A-1 / V.T. Miller, R.A. Muesing, J.C. LaRosa et al. // Obstet.
Gynecol. — 1991. — Vol. 77. — P. 235.
58. Whitehead M. Progestins and androgens // Fertil. Steril. — 1994. — Vol.
62. — P. 161S.
59. Hickok L.R., Toomey C., Speroff L. A comparison of esterified estrogens
with and without methyltestosterone: Effects on endometrial histology and
serum lipoproteins in postmenopausal women // Obstet. Gynecol. — 1993. —
Vol. 82. — P. 919.
60. Comparative effects of oral esterified estrogens with and without
methyltestosterone on endocrine profiles and dimensions of sexual function
in postmenopausal women with hypoactive sexual desire / R.A. Lobo, R.C.
Rosen, H.W. Yang et al. // Fertil. Steril. — 2003. — Vol. 79. — P. 1341.
61. Gambrell R.D., Teran A. Changes in lipids and lipoproteins with longterm
oestrogen deficiency and hormone replacement therapy // Am. J. Obstet.
Gynecol. — 1991. — Vol. 165. — P. 307.
62. Postmenopausal estrogen and androgen replacement and lipoprotein
lipid concentrations / B.B. Sherwin, M.M. Gelfand, R. Schucher et al. //
Ibid. — 1987. — Vol. 156. — P. 414.
63. Evidence that parenteral testosterone therapy may improve endotheliumdependent
and independent vasodilatation in postmenopausal women already
receiving estrogen / S. Worboys, D. Kotsopoulos, H. Teede et al. // J. Clin.
Endocrinol. Metab. — 2001. — Vol. 86. — P. 158.
64. Sands R., Studd J. Exogenous androgens in postmenopausal women //
Am. J. Med. — 1995. — Vol. 98, N 1A. — P. 76.
65. Long-term hormone implant therapy: Hormonal and clinical effects /
D.H. Barlow, H.I. Abdalla, A.D. Roberts et al. // Obstet. Gynecol. — 1986.
— Vol. 67. — P. 321.
66. Rosner B., Colditz G.A., Willett W.C. Reproductive risk factors in
a prospective study of breast cancer: The Nurses’ Health Study // Am. J.
Epidemiol. — 1994. — Vol. 139. — P. 819.
67. Colditz G.A., Frazier A.L. Models of breast cancer show that risk is set
by events of early life: Prevention efforts must shift focus // Cancer Epidemiol.
Biomarkers Prev. — 1995. — Vol. 4. — P. 567.
68. Rosner B., Colditz G.A. Nurses’ Health Study: Log-incidence mathematical
model of breast cancer incidence // J. Natl Cancer. Inst. — 1996. — Vol.
88. — P. 359.
69. Age at menarche, age at menopause, height and obesity as risk factors
for breast cancer: Associations and interactions in an international case-control
study / C.C. Hsieh, D. Trichopoulos, K. Katsouyanni et al. // Int. J. Cancer.
— 1990. — Vol. 46. — P. 796.
70. Key T., Appleby P., Barnes I. et al. Endogenous sex hormones and breast
cancer in postmenopausal women: reanalysis of nine prospective studies //
J. Natl Cancer Inst. — 2002. — Vol. 94. — P. 606.
71. Elevated serum estradiol and testosterone concentrations are associated
with a high risk for breast cancer / J.A. Cauley, F.L. Lucas, L.H. Kuller et
al. // Ann. Intern. Med. — 1999. — Vol. 130. — P. 270.
72. Plasma sex steroid hormone levels and risk of breast cancer in
postmenopausal women / S.E. Hankinson, W.C. Willett, J.E. Manson et al. //
J. Natl Cancer Inst. — 1998. — Vol. 90. — P. 1292.
73. Clemons M., Goss P. Mechanisms of disease: estrogen and the risk of
breast cancer // N. Engl. J. Med. — 2001. — Vol. 344. — P. 276.
74. Bone mineral density and risk of breast cancer in older women / J.A. Cauley,
F.L. Lucas, L.H. Kuller et al. // JAMA. — 1996. — Vol. 276. — P. 1404.
75. Bone mass and the risk of breast cancer among postmenopausal women /
Y. Zhang, D.P. Kiel, B.E. Kreger et al. // N. Engl. J. Med. — 1997. — Vol.
336. — P. 611.
76. Brisson J., Morrison A.S., Khalid N. Mammographic parenchymal features
and breast cancer in the breast cancer detection demonstration project //
J. Natl Cancer Inst. — 1988. — Vol. 80. — P. 1534.
77. Mammographic densities and breast cancer risk / N.F. Boyd, G.A.
Lockwood, J.W. Byng et al. // Cancer Epidemiol. Biomarkers Prev. — 1998.
— Vol. 7. — P. 1133.
78. Mammographic features and breast cancer risk: Effects with time, age,
and menopause status / C. Byrne, C. Scharier, J. Wolfe et al. // J. Natl Cancer
Inst. — 1995. — Vol. 87. — P. 1622.
79. Cyrlak D., Wong C.H. Mammographic changes in postmenopausal women
undergoing hormonal replacement therapy // AJR Am. J. Roentgenol. —
1993. — Vol. 161. — P. 1177.
80. Effects of estrogen and estrogen-progestin on mammographic
parenchymal density / G.A. Greendale, B.A. Reboussin, A. Sie et al. // Ann.
Intern. Med. — 1999. — Vol. 130. — P. 262.
81. Changes in breast density associated with initiation, discontinuation,
and continuing use of hormone replacement therapy / C.M. Rutter, M.T.
Mandelson, M.B. Laya et al. // JAMA. — 2001. — Vol. 285. — P. 171.
82. Effect of estrogen replacement therapy on the specificity and sensitivity
of screening mammography / M.B. Laya, E.B. Larson, S.H. Taplin et al. //
J. Natl Cancer Inst. — 1996. — Vol. 88. — P. 643.
83. Kavanagh A.M., Mitchell H., Giles G.G. Hormone replacement therapy
and accuracy of mammographic screening // Lancet. — 2000. — Vol. 355. —
P. 270.
84. Thurfjell E.L., Holmberg L.H., Persson I.R. Screening mammography:
Sensitivity and specificity in relation to hormone replacement therapy //
Radiology. — 1997. — Vol. 203. — P. 339.
85. Dual effects of weight and weight gain on breast cancer risk /
Z. Huang, S.E. Hankinson, G.A. Colditz et al. // JAMA. — 1997. — Vol.
278. — P. 1407.
86. Reversal of relation between body mass and endogenous estrogen
concentrations with menopausal status / N. Potischman, C.A. Swanson,
P. Siiteri et al. // J. Natl Cancer Inst. — 1996. — Vol. 88. — P. 756.
87. Alcohol, height, and adiposity in relation to estrogen and prolactin levels
in postmenopausal women / S.E. Hankinson, W.C. Willett, J.E. Manson et
al. // Ibid. — 1995. — Vol. 87. — P. 1297.
88. The use of estrogens and progestins and the risk of breast cancer in
postmenopausal women / G.A. Colditz, S.E. Hankinson, D.J. Hunter et al. //
N. Engl. J. Med. — 1995. — Vol. 332. — P. 1589.
89. The risk of breast cancer after estrogen and estrogen-progestin replacement /
L. Bergkvist, H.O. Adami, I. Persson et al. // Ibid. — 1989. — Vol. 321. —
P. 293.
90. Combined estrogen and progestin hormone replacement therapy in
relation to risk of breast cancer in middle-aged women / J.L. Stanford, N.S.
Weiss, L.F. Voigt et al. // JAMA. — 1995. — Vol. 274. — P. 137.
91. The role of hormone replacement therapy in the risk for breast cancer
and total mortality in women with a family history of breast cancer / T.A.
Sellers, P.J. Mink, J.R. Cerhan et al. // Ann. Intern. Med. — 1997. — Vol.
127. — P. 973.
92. Colditz G.A., Egan K.M., Stampfer M.J. Hormone replacement therapy
and risk of breast cancer: Results from epidemiologic studies // Am. J. Obstet.
Gynecol. — 1993. — Vol. 168. — P. 1473.
93. Estrogen replacement therapy and risk of fatal breast cancer in
a prospective cohort of postmenopausal women in the United States /
D.B. Willis, E.E. Calle, H.L. Miracle-McMahill et al. // Cancer Causes
Control. — 1996. — Vol. 7. — P. 449.
94. A meta-analysis of the effect of estrogen replacement therapy on the risk
of breast cancer / K.K. Steinberg, S.B. Thacker, S.J. Smith et al. // JAMA. —
1991. — Vol. 265. — P. 1985.
95. Breast cancer risk and duration of estrogen use: The role of study
design in meta-analysis / K.K. Steinberg, S.J. Smith, S.B. Thacker et al. //
Epidemiology. — 1994. — Vol. 5. — P. 415.
96. Erlik Y., Meldrum D.R., Judd H.L. Estrogen levels in postmenopausal
women with hot flashes // Obstet. Gynecol. — 1982. — Vol. 59. — P. 403.
97. Factors associated with appendicular bone mass in older women. The
Study of Osteoporotic Fractures Research Group / D.C. Bauer, W.S. Browner,
J.A. Cauley et al. // Ann. Intern. Med. — 1993. — Vol. 118. — P. 657.
98. Risks and benefits of estrogen and progestin in healthy postmenopausal
women: principal results from the Women’s Health Initiative randomized
controlled trial // JAMA. — 2002. — Vol. 288. — P. 321.
99. Colditz G.A. Relationship between estrogen levels, use of hormone
replacement therapy, and breast cancer // J. Natl Cancer Inst. — 1998. — Vol.
90. — P. 814.
100. Prior to use of estrogen replacement therapy, are users healthier
than nonusers? / K.A. Matthews, L.H. Kuller, R.R. Wing et al. // Am. J.
Epidemiol. — 1996. — Vol. 143. — P. 971.
101. Influence of Estrogen Plus Progestin on Breast Cancer and
Mammography in Healthy Postmenopausal Women: The Women’s Health
Initiative Randomized Trial / R.T. Chlebowski, S.L. Hendrix, R.D. Langer
et al. // JAMA. — 2003. — Vol. 289. — P. 3243.
102. Relationship between long durations and different regimens of hormone
therapy and risk of breast cancer / C.I. Li, K.E. Malone, P.L. Porter et al. //
Ibid. — N 24. — P. 3254–3263.
103. Menopausal estrogen and estrogen-progestin replacement therapy and
breast cancer risk [In Process Citation] / C. Schairer, J. Lubin, R. Troisi et
al. // Ibid. — 2000. — Vol. 283. — P. 485.
104. Effect of hormone replacement therapy on breast cancer / R.K. Ross,
A. Paganini-Hill, P.C. Wan et al. // J. Int. Cancer Inst. — 2000 — Vol. 92,
N 4. — P. 328–332.
105. Olsson H.L., Ingvar C., Bladstrom A. Hormone replacement therapy
containing progestins and given continuously increases breast carcinoma risk
in Sweden // Cancer. — 2003. — Vol. 97. — P. 1387.
106. Beral V. Breast cancer and hormone-replacement therapy in the Million
Women Study // Lancet. — 2003. — Vol. 362. — P. 419.
107. Clarke C., Sutherland R. Progestin regulation of cellular proliferation:
Update 1993 // Endocrine Reviews. Monograph I. Endocrine Aspects of
Cancer / ed. K. Horwitz. — Bethesda : Endocrine Society, 1993. — P. 132.
108. Hormone replacement therapy with estrogen or estrogen plus
medroxyprogesterone acetate is associated with increased epithelial proliferation
in the normal postmenopausal breast [In Process Citation] / L.J. Hofseth,
A.M. Raafat, J.R. Osuch et al. // J. Clin. Endocrinol. Metab. — 1999. — Vol.
84. — P. 4559.
109. Effects of hormone replacement therapy on the mammary gland of
surgically post-menopausal cynomolgus macaques / J.M. Cline, G. Soderqvist,
E. von Schoultz et al. // Am. J. Obstet. Gynecol. — 1996. — Vol. 174. — P. 93.
110. Wren B. Hormonal replacement therapy and breast cancer // Eur.
Menopause J. — 1995. — Vol. 2. — P. 13.
111. Use of postmenopausal hormones, alcohol, and risk for invasive breast
cancer / W.Y. Chen, G.A. Colditz, B. Rosner et al. // Ann. Intern. Med. —
2002. — Vol. 137. — P. 798.
112. The role of hormone replacement therapy in the risk for breast cancer
and total mortality in women with a family history of breast cancer / T.A.
Sellers, P.J. Mink, J. Cerhan et al. // Ibid. — 1997. — Vol. 127. — P. 973.
113. Postmenopausal hormone therapy and mortality / F. Grodstein,
M.J. Stampfer, G.A. Colditz et al. // N. Engl. J. Med. — 1997. — Vol. 336. —
P. 1769.
114. Assessment and counseling for women with a family history of breast
cancer. A guide for clinicians / K.F. Hoskins, J.E. Stopfer, K.A. Calzone et
al. // JAMA. — 1995. — Vol. 273. — P. 577.
115. Guidelines for counseling postmenopausal women about preventive
hormone therapy. American College of Physicians // Ann. Intern. Med. —
1992. — Vol. 117. — P. 1038.
116. Colditz G.A., Rosner B.A., Speizer F.E. Risk factors for breast cancer
according to family history of breast cancer // J. Natl Cancer Inst. — 1996. — Vol.
88. — P. 365.
117. Estrogen replacement therapy in breast cancer survivors: A time for
change / M.A. Cobleigh, R.F. Berris, T. Bush et al. // JAMA. — 1994. — Vol.
272. — P. 540.
118. Vassilopoulou-Sellin R., Theriault R., Klein M.J. Estrogen replacement
therapy in women with prior diagnosis and treatment for breast cancer //
Gynecol. Oncol. — 1997. — Vol. 65. — P. 89.
119. Estrogen replacement therapy after localized breast cancer: Clinical
outcome of 319 women followed prospectively / R. Vassilopoulou-Sellin,
L. Asmar, G.N. Hortobagyi et al. // J. Clin. Oncol. — 1999. — Vol. 17. —
P. 1482.
120. Hormone replacement therapy in breast cancer survivors: A cohort study /
P.J. DiSaia, E.A. Grosen, T. Kurosaki et al. // Am. J. Obstet. Gynecol. —
1996. — Vol. 174. — P. 1494.
121. Natrajan P.K., Soumakis K., Gambrell R.D.Jr. Estrogen replacement
therapy in women with previous breast cancer // Ibid. — 1999. — Vol. 181. —
P. 288.
122. Hormone replacement therapy after treatment of breast cancer: effects
on postmenopausal symptoms, bone mineral density and recurrence rates /
M.W. Beckmann, D. Jap, S. Djahansouzi et al. // Oncology. — 2001. — Vol.
60. — P. 199.
123. Hormone replacement therapy after breast cancer: a systematic review
and quantitative assessment of risk / N.F. Col, L.K. Hirota, R.K. Orr et al. //
J. Clin. Oncol. — 2001. — Vol. 19. — P. 2357.
124. Hormone replacement therapy after a diagnosis of breast cancer in
relation to recurrence and mortality / E.S. O’Meara, M.A. Rossing, J.R. Daling
et al. // J. Natl Cancer Inst. — 2001. — Vol. 93. — P. 754.
125. Estrogen replacement therapy for menopausal women with a history
of breast carcinoma / R. Vassilopoulou-Sellin, D.S. Cohen, G.N. Hortobagyi
et al. // Cancer. — 2002. — Vol. 95. — P. 1817.
126. Creasman W.T. Estrogen replacement therapy: Is previously treated
cancer a contraindication? // Obstet. Gynecol. — 1991. — Vol. 77. — P. 308.
127. Nanda K., Bastian L.A., Schulz K. Hormone replacement therapy and
the risk of death from breast cancer: a systematic review // Am. J. Obstet.
Gynecol. — 2002. — Vol. 186. — P. 325.
128. Prognosis after breast cancer diagnosis in women exposed to estrogen
and estrogen-progestogen replacement therapy / L. Bergkvist, H.-O. Adami,
I. Persson et al. // Am. J. Epidemiol. — 1989. — Vol. 130. — P. 221.
129. The relationship between breast cancer survival and prior postmenopausal
estrogen use / D.M. Strickland, R.D.Jr. Gambrell, C.A. Butzin et al. // Obstet.
Gynecol. — 1992. — Vol. 80. — P. 400.
130. Postmenopausal hormone replacement therapy: Effect on diagnosis
and outcome in early-stage invasive breast cancer treated with conservative
surgery and radiation / B. Fowble, A. Hanlon, G. Freedman et al. // J. Clin.
Oncol. — 1999. — Vol. 17. — P. 1680.
131. Holli K., Isola J., Cuzick J. Low biologic aggressiveness in breast cancer
in women using hormone replacement therapy // Ibid. — 1998. — Vol. 16. —
P. 3115.
132. Gapstur S.M., Morrow M., Sellers T.A. Hormone replacement therapy
and risk of breast cancer with a favorable histology. Results of the Iowa
Women’s Health Study // JAMA. — 1999. — Vol. 281. — P. 2091.
133. Bush T.L., Whiteman M.K. Hormone replacement therapy and risk of
breast cancer // Ibid. — P. 2140.
134. Hormone replacement therapy in relation to risk of lobular and ductal
breast carcinoma in middle-aged women / C.I. Li, N.S. Weiss, J.L. Stanford
et al. // Cancer. — 2000. — Vol. 88. — P. 2570.
135. Hormone replacement therapy in relation to breast cancer / C.L. Chen,
N.S. Weiss, P. Newcomb et al. // JAMA. — 2002. — Vol. 287. — P. 734.
136. Henderson B.E., Paganini-Hill A., Ross R.K. Decreased mortality in
users of estrogen replacement therapy // Arch. Intern. Med. — 1991. — Vol.
151. — P. 75.
137. Reduced mortality associated with long-term postmenopausal estrogen
therapy / B. Ettinger, G.D. Friedman, T. Bush et al. // Obstet. Gynecol. —
1996. — Vol. 87. — P. 6.
138. Estrogen replacement therapy and mortality among older women. The
Study of Osteoporotic Fractures / J.A. Cauley, D.G. Seeley, W.S. Browner et
al. // Arch. Intern. Med. — 1997. — Vol. 157. — P. 2181.
139. Pinkerton J.V., Santen R. Alternatives to the use of estrogen in
postmenopausal women // Endocr. Rev. — 1999. — Vol. 20. — P. 308.
140. Santen R.J., Petroni G. Relative versus attributable risk of breast cancer
from estrogen replacement therapy // J. Clin. Endocrinol. Metab. — 1999. —
Vol. 84. — P. 1875.
141. Fulton J.P. New guidelines for the prevention and treatment of
osteoporosis. National Osteoporosis Foundation // Med. Health. RI. — 1999. —
Vol. 82. — P. 110.
142. Noninvasive assessment of bone mineral and structure: State of the art /
H.K. Genant, K. Engelke, T. Fuerst et al. // J. Bone Miner. Res. — 1996. —
Vol. 11. — P. 707.
143. Wolinsky F.D., Fitzgerald J.F., Stump T.E. The effect of hip fracture on
mortality, hospitalization, and functional status: A prospective study // Am.
J. Public Health. — 1997. — Vol. 87. — P. 398.
144. Manson J.E., Martin K.A. Clinical practice. Postmenopausal hormonereplacement
therapy // N. Engl. J. Med. — 2001. — Vol. 345. — P. 34.
145. Risks and benefits of estrogen and progestin in healthy postmenopausal
women: principal results from the Women’s Health Initiative randomized
controlled trial // JAMA. — 2002. — Vol. 288. — P. 321.
146. For the Heart and Estrogen/progestin Replacement Study (HERS)
Research Group. Randomized trial of estrogen plus progestin for secondary
prevention of coronary heart disease in postmenopausal women / S. Hulley,
D. Grady, T. Bush et al. // Ibid. — 1998. — Vol. 280. — P. 605.
147. Cardiovascular disease outcomes during 6.8 years of hormone therapy:
Heart and Estrogen/progestin Replacement Study follow-up (HERS II) /
D. Grady, D. Herrington, V. Bittner et al. // Ibid. — 2002. — Vol. 288. — P. 49.
148. Noncardiovascular disease outcomes during 6.8 years of hormone
therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS
II) / S. Hulley, C. Furberg, E. Barrett-Connor et al. // Ibid. — 2002. — Vol.
288, N 1. — P. 58.
149. Hormone replacement therapy for African American women: missed
opportunities for effective intervention / W.K. Nicholson, A.F. Brown,
J. Gathe et al. // Menopause. — 1999. — Vol. 6. — P. 147.
150. Effects of gender and race on prognosis after myocardial infarction: adverse
prognosis for women, particularly black women / G.H. Tofler, P.H. Stone, J.E.
Muller et al. // J. Am. Coll. Cardiol. — 1987. — Vol. 9. — P. 473.
151. Trends and disparities in coronary heart disease, stroke, and other
cardiovascular diseases in the United States: findings of the national conference
on cardiovascular disease prevention / R. Cooper, J. Cutler, P. DesvigneNickens et al. // Circulation (Online). — 2000. — Vol. 102. — P. 3137.
152. How many women have osteoporosis? / L.J. III Melton, E.A. Chrischilles,
C. Cooper et al. // J. Bone Miner. Res. — 1992. — Vol. 7. — P. 1005.
153. Changes in vertebral bone density in black girls and white girls during
childhood and puberty / V. Gilsanz, T. Roe, S. Mora et al. // N. Engl. J.
Med. — 1991. — Vol. 325. — P. 1597.
154. Racial differences in pre- and postmenopausal bone homeostasis:
association with bone density / D. Meier, M. Luckey, S. Wallenstein et al. //
J. Bone Miner. Res. — 1992. — Vol. 7. — P. 1181.
155. Myers L.S., Dixen J., Morrissette D. Effects of estrogen, androgen, and
progestin on sexual psychophysiology and behavior in postmenopausal women
// J. Clin. Endocrinol. Metab. — 1990. — Vol. 70. — P. 1124.
156. Grady D. A 60-year-old woman trying to discontinue hormone
replacement therapy // JAMA. — 2002. — Vol. 287. — P. 2130.
157. Bone response to termination of oestrogen treatment / R. Lindsay,
A. MacLean, A. Kraszewski et al. // Lancet. — 1978. — Vol. 1. — P. 1325.
158. Christiansen C., Christensen M.S., Transbol I. Bone mass in
postmenopausal women with withdrawal of oestrogen/gestagen replacement
therapy // Ibid. — 1981. — Vol. 1. — P. 459.
159. The effect of postmenopausal estrogen therapy on bone density in
elderly women / D.T. Felson, Y. Zhang, M.T. Hannan et al. // N. Engl. J.
Med. — 1993. — Vol. 329. — P. 1141.
160. Calcium supplementation with and without hormone replacement
therapy to prevent postmenopausal bone loss / J.F. Aloia, A. Vaswani, J.K.
Yeh et al. // Ann. Intern. Med. — 1994. — Vol. 120. — P. 97.
161. Meta-analyses of therapies for postmenopausal osteoporosis // Endocr.
Rev. — 2002. — Vol. 23. — P. 495.
162. Hypovitaminosis D in medical inpatients / M.K. Thomas, D.M.
Lloyd-Jones, R.I. Thadhani et al. // N. Engl. J. Med. — 1998. — Vol. 338. —
P. 777.
163. Vitamin D deficiency in homebound elderly persons / F.M. Gloth,
C.M. Gundberg, B.W. Hollis et al. // JAMA. — 1995. — Vol. 274. —
P. 1683.
164. Effect of changes in weight-bearing exercise on lumbar bone mass after
age fifty / B.A. Michel, N.E. Lane, D.A. Bloch et al. // Ann. Med. — 1991. —
Vol. 23. — P. 397.
165. Therapeutic equivalence of alendronate 70 mg once-weekly and
alendronate 10 mg daily in the treatment of osteoporosis. Alendronate OnceWeekly Study Group / T. Schnitzer, H.G. Bone, G. Crepaldi et al. // Aging
(Milano). — 2000. — Vol. 12. — P. 1.
166. Two-year effects of alendronate on bone mineral density and vertebral
fracture in patients receiving glucocorticoids: a randomized, double-blind,
placebo-controlled extension trial / J.D. Adachi, K.G. Saag, P.D. Delmas et
al. // Arthritis Rheum. — 2001. — Vol. 44. — P. 202.
167. Effect of oral alendronate on bone mineral density and the incidence
of fractures in postmenopausal osteoporosis / U.A. Liberman, S.R. Weiss, J.
Broll et al. // N. Engl. J. Med. — 1995. — Vol. 333. — P. 1437.
168. Prevention of bone loss with alendronate in postmenopausal women
under 60 years of age / D. Hosking, C.E. Chilvers, C. Christiansen et al. //
Ibid. — 1998. — Vol. 338. — P. 485.
169. Alendronate prevents postmenopausal bone loss in women without
osteoporosis. A double-blind, randomized, controlled trial / M. McClung,
B. Clemmesen, A. Daifotis et al. // Ann. Intern. Med. — 1998. — Vol. 128. —
P. 253.
170. Skeletal benefits of alendronate: 7-year treatment of postmenopausal
osteoporotic women / R.P. Tonino, P.J. Meunier, R. Emkey et al. // J. Clin.
Endocrinol. Metab. — 2000. — Vol. 85. — P. 3109.
171. Cyclical etidronate in the treatment of postmenopausal osteoporosis:
Efficacy and safety after seven years of treatment / P.D. Miller, N.B. Watts,
A.A. Licata et al. // Am. J. Med. — 1997. — Vol. 103. — P. 468.
172. A double-blind, placebo-controlled, dose-finding trial of intermittent
nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone
loss / J.Y. Reginster, R. Deroisy, M.P. Lecart et al. // Ibid. — 1995. — Vol.
98. — P. 452.
173. A 5-year controlled randomized study of prevention of postmenopausal
trabecular bone loss with nasal salmon calcitonin and calcium / J.Y. Reginster,
L. Meurmans, R. Deroisy et al. // Eur. J. Clin. Invest. — 1994. — Vol. 24. —
P. 565.
174. Effect of salcatonin given intranasally on bone mass and fracture rates in
established osteoporosis: A dose-response study / K. Overgaard, M.A. Hansen,
S.B. Jensen et al. // BMJ. — 1992. — Vol. 305. — P. 556.
175. A randomized trial of nasal spray salmon calcitonin in postmenopausal
women with established osteoporosis: the prevent recurrence of osteoporotic
fractures study / C.H. Chesnut III, S. Silverman, K. Andriano et al. // Am.
J. Med. — 2000. — Vol. 109. — P. 267.
176. Effects of tamoxifen on bone mineral density in postmenopausal women
with breast cancer / R.R. Love, R.B. Mazess, H.S. Barden et al. // N. Engl.
J. Med. — 1992. — Vol. 326. — P. 852.
177. Effect of tamoxifen on bone mineral density measured by dual-energy
x-ray absorptiometry in healthy premenopausal and postmenopausal women /
T.J. Powles, T. Hickish, J.A. Kanis et al. // J. Clin. Oncol. — 1996. — Vol.
14. — P. 78.
178. Cardiovascular effects of tamoxifen in women with and without
heart disease: Breast Cancer Prevention Trial / S.E. Reis, J.P. Costantino,
D.L. Wickerham et al. // J. Natl Cancer Inst. — 2001. — Vol. 93. — P. 16.
179. Five versus more than five years of tamoxifen therapy for breast cancer
patients with negative lymph nodes and estrogen receptor-positive tumors / B.
Fisher, J. Dignam, J. Bryant et al. // Ibid. — 1996. — Vol. 88. — P. 1529.
180. Effects of raloxifene on bone mineral density, serum cholesterol
concentrations, and uterine endometrium in postmenopausal women /
P.D. Delmas, N.H. Bjarnason, B.H. Mitlak et al. // N. Engl. J. Med. — 1997. —
Vol. 337. — P. 1641.
181. Reduction of vertebral fracture risk in postmenopausal women with
osteoporosis treated with raloxifene / B. Ettinger, D.M. Black, B.H. Mitlak
et al. // JAMA. — 1999. — Vol. 282. — P. 637.
182. Continued breast cancer risk reduction in postmenopausal women
treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes
of raloxifene evaluation / J.A. Cauley, L. Norton, M.E. Lippman et al. //
Breast Cancer Res. Treat. — 2001. — Vol. 65. — P. 125.
183. Clarkson T.B., Anthony M.S., Jerome C.P. Lack of effect of raloxifene
on coronary artery atherosclerosis of postmenopausal monkeys // J. Clin.
Endocrinol. Metab. — 1998. — Vol. 83. — P. 721.
184. Venlafaxine in management of hot flashes in survivors of breast cancer:
a randomised controlled trial / C.L. Loprinzi, J.W. Kugler, J.A. Sloan et al. //
Lancet. — 2000. — Vol. 356. — P. 2059.
185. Paroxetine controlled release in the treatment of menopausal hot
flashes: a randomized controlled trial / V. Stearns, K.L. Beebe, M. Iyengar et
al. // JAMA. — 2003. — Vol. 289. — P. 2827.
186. Phase III Evaluation of Fluoxetine for Treatment of Hot Flashes /
C.L. Loprinzi, J.A. Sloan, E.A. Perez et al. // J. Clin. Oncol. — 2002. — Vol.
20. — P. 1578.
187. Megestrol acetate for the prevention of hot flashes / C.L. Loprinzi,
J.C. Michalak, S.K. Quella et al. // N. Engl. J. Med. — 1994. — Vol. 331. —
P. 347.
188. Intramuscular depot medroxyprogesterone versus oral megestrol for the
control of postmenopausal hot flashes in breast cancer patients: a randomized
study / G. Bertelli, M. Venturini, L. Del Mastro et al. // Ann. Oncol. — 2002. —
Vol. 13. — P. 883.
189. Effect of clonidine on hot flashes in postmenopausal women /
L.R. Laufer, Y. Erlik, D.R. Meldrum et al. // Obstet. Gynecol. — 1982. —
Vol. 60. — P. 583.
190. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes /
R.M. Goldberg, C.L. Loprinzi, J.R. O’Fallon et al. // J. Clin. Oncol. — 1994. —
Vol. 12. — P. 155.
191. Clayden J.R., Bell J.W., Pollard P. Menopausal flushing: double-blind trial
of a non-hormonal medication // Br. Med. J. — 1974. — Vol. 1. — P. 409.
192. Nagamani M., Kelver M.E., Smith E.R. Treatment of menopausal hot
flashes with transdermal administration of clonidine // Am. J. Obstet. Gynecol. —
1987. — Vol. 156. — P. 561.
193. Oral clonidine in postmenopausal patients with breast cancer experiencing
tamoxifen-induced hot flashes: A University of Rochester Cancer Center
Community Clinical Oncology Program Study / K.J. Pandya, R.F. Raubertas,
P.J. Flynn et al. // Ann. Intern. Med. — 2000. — Vol. 132. — P. 788.
194. Veralipride: Alternative antidopaminergic treatment for menopausal
symptoms / A. David, R. Don, G. Tajchner et al. // Am. J. Obstet. Gynecol. —
1988. — Vol. 158. — P. 1107.
195. Gabapentin’s effects on hot flashes in postmenopausal women: a
randomized controlled trial / T. Guttuso, R. Kurlan, M.P. McDermott et al. //
Obstet. Gynecol. — 2003. — Vol. 101. — P. 337.
196. Pilot evaluation of gabapentin for treating hot flashes / L. Loprinzi,
D.L. Barton, J.A. Sloan et al. // Mayo Clin. Proc. — 2002. — Vol. 77. —
P. 1159.
197. Fitzpatrick L.A., Santen R.J. Hot flashes: the old and the new, what is
really true? // Ibid. — N 11. — P. 1155–1158.
198. Effect of soy phytoestrogens on hot flashes in postmenopausal women
with breast cancer: a randomized, controlled clinical trial / C.L. Van Patten,
I.A. Olivotto, G.K. Chambers et al. // J. Clin. Oncol. — 2002. — Vol. 20. —
P. 1449.
199. Vasomotor symptom relief by soy isoflavone extract tablets in
postmenopausal women: a multicenter, double-blind, randomized, placebocontrolled
study / D.H. Upmalis, R. Lobo, L. Bradley et al. // Menopause. —
2000. — Vol. 7. — P. 236.
200. Evaluation of soy phytoestrogens for the treatment of hot flashes in
breast cancer survivors: A North Central Cancer Treatment Group Trial /
S.K. Quella, C.L. Loprinzi, D.L. Barton et al. // J. Clin. Oncol. — 2000. —
Vol. 18. — P. 1068.
201. Kronenberg F., Fugh-Berman A. Complementary and alternative
medicine for menopausal symptoms: a review of randomized, controlled trials //
Ann. Intern. Med. — 2002. — Vol. 137. — P. 805.
202. A randomized placebo-controlled crossover trial with phytoestrogens
in treatment of menopause in breast cancer patients / E. Nikander,
A. Kilkkinen, M. Metsa-Heikkila et al. // Obstet. Gynecol. — 2003. — Vol.
101. — P. 1213.
203. Phytoestrogen supplements for the treatment of hot flashes: The
Isoflavone Clover Extract (ICE) Study: A Randomized Controlled Trial /
J.A. Tice, B. Ettinger, K. Ensrud et al. // JAMA. — 2003. — Vol. 290. —
P. 207.
204. Messina M.J., Loprinzi C.L. Soy for breast cancer survivors: a critical
review of the literature // J. Nutr. — 2001. — Vol. 131. — P. 3095S.
205. Nachtigall L.E. Comparative study: Replens versus local estrogen in
menopausal women // Fertil. Steril. — 1994. — Vol. 61. — P. 178.
206. Biological effects of various doses of vaginally administered conjugated
equine estrogens in postmenopausal women / F.P. Mandel, F.L. Geola,
D.R. Meldrum et al. // J. Clin. Endocrinol. Metab. — 1983. — Vol. 57. —
P. 133.
207. Raz R., Stamm W.E. A controlled trial of intravaginal estriol in
postmenopausal women with recurrent urinary tract infections // N. Engl. J.
Med. — 1993. — Vol. 329. — P. 753.
208. Baker V.L. Alternatives to oral estrogen replacement: Transdermal
patches, percutaneous gels, vaginal creams and rings, implants, and other
methods of delivery // Obstet. Gynecol. Clin. North Am. — 1994. — Vol.
21. — P. 271.
209. Treatment of urogenital atrophy with low-dose estradiol: preliminary
results / R.J. Santen, J.V. Pinkerton, M. Conaway et al. // Menopause. —
2002. — Vol. 9. — P. 179.
210. A comparative multicenter study of the effects of continuous low-dose
estradiol released from a new vaginal ring versus estriol vaginal pessaries in
postmenopausal women with symptoms and signs of urogenital atrophy / L.
Henriksson, M. Stjernquist, L. Boquist et al. // Am. J. Obstet. Gynecol. —
1994. — Vol. 171. — P. 624.
211. Oestradiol-releasing vaginal ring for treatment of postmenopausal
urogenital atrophy / P. Smith, G. Heimer, M. Lindskog et al. // Maturitas. —
1993. — Vol. 16. — P. 145.
212. Vaginal administration of low-dose conjugated estrogens: Systemic
absorption and effects on the endometrium / V.L. Handa, K.E. Bachus, W.W.
Johnston et al. // Obstet. Gynecol. — 1994. — Vol. 84. — P. 215.
213. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors
in normal postmenopausal women / A.B. Grey, J.P. Stapleton, M.C. Evans et
al. // J. Clin. Endocrinol. Metab. — 1995. — Vol. 80. — P. 3191.
214. Tamoxifen inhibits arterial accumulation of LDL degradation products
and progression of coronary artery atherosclerosis in monkeys / J.K. Williams,
J.D. Wagner, Z. Li et al. // Arterioscler. Thromb. Vasc. Biol. — 1997. — Vol.
17. — P. 403.
215. Effects of the antiestrogen tamoxifen on low-density lipoprotein
concentrations and oxidation in postmenopausal women / V. Guetta,
R.M. Lush, W.D. Figg et al. // Am. J. Cardiol. — 1995. — Vol. 76. — P. 1072.
216. Tamoxifen for early breast cancer: an overview of the randomized
trials. Early Breast Cancer Trialists’ Collaborative Group // Lancet. — 1998. —
Vol. 351. — P. 1451.
217. Design and methods of the Raloxifene Use for The Heart (RUTH)
study / L. Mosca, E. Barrett-Connor, N.K. Wenger et al. // Am. J. Cardiol. —
2001. — Vol. 88. — P. 392.
218. Natrajan P.K., Soumakis K., Gambrell R.D.Jr. Estrogen replacement
therapy in women with previous breast cancer // Am. J. Obstet. Gynecol. —
1999. — Vol. 181. — P. 288.
219. Hormone replacement therapy after treatment of breast cancer: effects
on postmenopausal symptoms, bone mineral density and recurrence rates /
M.W. Beckmann, D. Jap, S. Djahansouzi et al. // Oncology. — 2001. — Vol.
60. — P. 199.
220. Estrogen replacement therapy / M.A. Cobleigh, R.F. Berris, T. Bush
et al. // JAMA. — 1994. — Vol. 272. — P. 540.
221. Breast cancer survival and hormone replacement therapy: a cohort
analysis / P.J. DiSaia, W.R. Brewster, A. Ziogas et al. // Am. J. Clin. Oncol. —
2000. — Vol. 23. — P. 541.
222. Treatment of estrogen deficiency symptoms in women surviving breast
cancer. The Hormone Foundation, Canadian Breast Cancer Research Initiative,
National Cancer Institute of Canada, Endocrine Society, and the University of
Virginia Cancer Center and Woman’s Place // J. Clin. Endocrinol. Metab. —
1998. — Vol. 83. — P. 1993.
223. Estrogen-progestin replacement therapy and endometrial cancer /
M.C. Pike, R.K. Peter, W. Cozen et al. // J. Natl. Cancer. Inst. — 1997. —
Vol. 89. — P. 1110.
224. Pike M.C., Ross R.K. Progestins and menopause: epidemiological
studies of risks of endometrial and breast cancer // Steroids. — 2000. — Vol.
65. — P. 659.
225. The use of estrogens and progestins and the risk of breast cancer in
postmenopausal women / G.A. Colditz, S.E. Hankinson, D.J. Hunter et al. //
N. Engl. J. Med. — 1995. — Vol. 332. — P. 1589.
226. Santen R.J., Petroni G. Relative versus attributable risk of breast cancer
from estrogen replacement therapy // J. Clin. Endocrinol. Metab. — 1999. —
Vol. 84. — P. 1875.
227. Risk of breast cancer with progestins in combination with estrogen as
hormone replacement therapy / R.J. Santen, J. Pinkerton, C. McCartney et
al. // Ibid. — 2001. — Vol. 86. — P. 16.
228. Prognosis after breast cancer diagnosis in women exposed to estrogen
and estrogen-progestogen replacement therapy / L. Bergkvist, H.-O. Adami,
I. Persson et al. // Am. J. Epidemiol. — 1989. — Vol. 130. — P. 221.
229. Gapstur S.M., Morrow M., Sellers T.A. Hormone replacement therapy
and risk of breast cancer with a favorable histology // JAMA. — 1999. — Vol.
281. — P. 2091.
230. Blakeman P.J., Hilton P., Bulmer J.N. Oestrogen and progesterone
receptor expression in the female iower urinary tract, with reference to
oestrogen status // BJU Int. — 2000. — Jul. — Vol. 86, N 1. — P. 32–36.
231. Mouse urogenital development: a practical approach / A. Staack,
A.A. Donjacour, J. Brody et al. // Differentiation. — 2003. — Vol. 71. —
P. 402–413.
232. Raco S. Testosterone supplemental therapy after hysterectomy with or
without concomitant oophorectomy: estrogen alone is not enough // J. Womens
Health Gend. Based Med. — 2000. — Vol. 9, N 8. — P. 917–923.
233. Sarcola T., Adlercreutz H., Heinonen S., Eriksson C.J.P. Alcohol intake,
androgen and glucocorticoid steroids in premenopausal women using oral
contraceptives: an interventional study // J. Steroid Biochem. Mol. Biol. —
2001. — Vol. 78, N 2. — P. 157–165.
234. Aldea M.J. Testosterone treatment in menopausal women // J. Clin.
Endocrinol. Metab. — 2003. — Vol. 87, N 7. — P. 2523–2526.
235. Carroll D.G., Noble S.L. Hormone replacement therapy: current
concerns and considerations // Am. J. Manag. Care. — 2002. — Vol. 8, N 7.
— P. 663–675.
236. Giske L.E., Hall G., Rud T., Landgren B.M. The effect of 17b-estradiol
at doses of 0,5, 1 and 2 mg compared with placebo on early postmenopausal
bone loss in hysterectomized women // Osteoporos. Int. — 2002. — Vol. 13,
N 4. — P. 309–316.
237. Salmen T., Heikkinen A.M., Mahonen A. Relation of androgen
receptor gene polymorphism to bone mineral density and fracture risk in early
postmenopausal women during a 5-year randomized hormone replacement
therapy trial // J. Bone Miner. Res. — 2003. — Vol. 18, N 2. — P. 319–324.
238. Hardy R., Kuh D. Change in psychological and vasomotor symptom
reporting during the menopause // Soc. Sci. Med. — 2002. — Vol. 55, N 11. —
P. 1975–1988.
239. La Valleur J. Counseling the perimenopausal women // Obstet.
Gynecol. Clin. North Am. — 2002. — Sep. — Vol. 29, N 3. — P. 541–553.
240. Shors T.J., Leuner B. Estrogen-mediated effects on depression and
memory formation in females // J. Affect. Disord. — 2003. — Mar. — Vol.
74. — P. 85–96.
241. Soares C.N., Poitras J.R., Prouty J. Effect of reproductive hormones
and selective estrogen receptor modulators on mood during menopause //
Drugs Aging. — 2003. — Vol. 20. — P. 85–100.
242. Harlow B.L., Wise L.A., Otto M.W. et al. Depression and its influence
on reproductive endocrine and menstrual cycle markers associated with
perimenopause // Arch. Gen. Psychiatry. — 2003. — Jan. — Vol. 60. —
P. 29–36.
243. Schmidt P.J., Murphy J.H., Haq J. et al. Basal plasma hormone levels
in depressed perimenopausal women // Psychoneuroendocrinology. — 2002. —
Nov. — Vol. 27. — P. 907–920.
244. Grigoriardis S., Kennedy S.H. Role estrogen in the treatment of
depression // Am. J. Ther. — 2002. — Vol. 9. — P. 503–509.
245. Stoppe G., Doren M. Critical appraisal of effects of estrogen replacement
therapy on symptoms of depressed mood // Arch. Women Ment. Health. —
2002. — Oct. — Vol. 5. — P. 39–47.
246. Korhonen S., Hippelainen M., Vanhala M. et al. The androgenic sex
hormone profile is an essential feature of metabolic syndrome in premenopausal
women: a controlled community-based study // Fertil. Steril. — 2003. — Vol.
79, N 6. — P. 1327–1334.
247. Burd I.D., Bachmann G.A. Androgen replacement in menopause // Curr.
Womens Health. Rep. — 2001. — Dec. — Vol. 1, N 3. — P. 202–205.
248. Brown W.R., Mishra G.D., Dobson A. Changes in physical symptoms
during the menopause transition // Int. J. Behav. Med. — 2002. — Vol. 9,
N 1. — P. 53–67.
249. Carranza-Lira S., Fragoso-Diaz N., MacGregor-Gooch A.L. et al. Vaginal
dryness assessment in postmenopausal women using pH test strip // Maturitas. —
2003. — Vol. 45. — P. 55–58.
250. Whiteman M.K., Staropoli C.A., Langenberg P.W. et al. Smoking, body
mass and hot flashes in midlife women // Obstet. Gynecol. — 2003. — Vol.
101, N 2. — P. 264–272.
251. Knapp K.M., Blake G.M., Fogelman I. et al. Multisite quantitative
ultrasound: Colles’ fracture discrimination in postmenopausal women //
Osteoporos. Int. — 2002. — Vol. 13, N 6. — P. 474–479.
252. Kawecka-Jaszcz K., Czarnecka D., Olszanecka A. et al. The effect
of hormone replacement therapy on arterial blood pressure and vascular
compliance in postmenopausal women with arterial hypertension // J. Hum.
Hypertens. — 2002. — Vol. 16, N 7. — P. 509–516.
253. Newton K.M., Buist D.S., Keenan N.L. et al. Use of alternative therapies
for menopausal symptoms: results of a population-based survey (1) // Obstet.
Gynecol. — 2002. — Vol. 100, N 1. — P. 18–25.
254. Tinelli F.G., Tinelli A., Sena T. Clinical effects hormone replacement
therapy with estradiol valerate and cyproterone acetate in perimenopausal
women // Minerva Gynecol. — 2002. — Feb. — Vol. 54, N 1. — P. 67–73.
255. Longcope C. Endocrine function of the postmenopausal ovary //
J. Soc. Gynecol. Investig. — 2001. — Vol. 8, N 1. – Suppl. Proccedings. —
P. 67–68.
256. Lange-Collett J. Promoting health among perimenopausal women
through diet and exercise // J. Am. Acad. Nurse Pract. — 2002. — Vol. 14,
N 4. — P. 172–177.
257. Estrogen replacement therapy in the treatment of major depressive
disorder in perimenopausal women / N.L. Rasgon, L.L. Altshuler, L.A.
Fairbanks et al. // J. Clin. Psychiatry. — 2002. — Vol. 63, N 7. —
P. 45–48.
258. Rohr U.D. The impact of testosterone imbalance on depression and
women’s health // Maturitas. — 2002. — Vol. 41, N 1. — P. 25–46.
259. The relationship of actual height loss with health-seeking behaviors
and risk factors in perimenopausal and menopausal women / J.J. Twiss, A.L.
Dillon, J.M. Konfrst et al. // J. Am. Acad. Nurse Pract. — 2002. — Vol. 14,
N 3. — P. 131–137.
260. Nguyen J.K., Bhatia N.N. Risk of recurrent stress incontinence in
women undergoing the combined modified pereyra procedure and transvaginal
sacrospinosus ligament vault suspension // Ceska Gynecol. — 2001. — Vol.
66, N 5. — P. 340–345.
261. Magnetic resonance in urogynecology / M. Otcenasek, M. Halaska,
J. Zizka et al. // J. Urol. — 2001. — Vol. 166, N 6. — P. 2263–2266.
262. Nguyen J.K., Bhatia N.N. Resolution of motor urge incontinence after
surgical repair of pelvic organ prolapse // Surg. Oncol. Clin. N. Am. — 2001. —
Vol. 10, N 3. — P. 557–569.
263. Combined genitourinary prolapse repair and prophylactic tensionfree
vaginal tape in women with severe prolapse and occult stress urinary
incontinence: preliminary results / D. Cordon, R.S. Gold, D. Pauzner et al. //
Urology. — 2001. — Vol. 58, N 4. — P. 544–546.
264. Cordon D., Groutz A. Evaluation of female lower urinary tract symptoms:
overview and update // Am. J. Obstet. Gynecol. — 2001. — Vol. 185, N 2. —
P. 345–348.
265. Brown J.S. Epidemiology and changing demographics of bladder: a
focus on the postmenopausal women // Geriatrics. — 2002. — Vol. 57. N 1. —
P. 29–34.
266. DuBeau C.E. The continuum of urinary incontinence in an aging
population // Radiology. — 2002. — Vol. 223, N 3. — P. 767–771.
267. Dmochowski R.R. Management of postoperative overactive bladder
complications // Geriatrics. — 2002. — Vol. 57, N 1. — P. 12–17.
268. Pubovaginal sling and pelvic prolapse repair in women with occult stress
urinary incontinence: effect on postoperative emptying and voiding symptoms /
N.M. Barnes, R.R. Dmochowski, R. Park et al. // Urology. — 2002. — Vol.
59, N 6. — P. 856–860.
269. Overactive bladder patients and role of the pharmacist / K. Stewart,
W.F. McGhan, T. Offerdahl et al. // Am. Pharm Assoc. — 2002. — Vol. 42,
N 3. — P. 469–476, 477–478.
270. Rechberger P. Urinary incontinence in women — diagnostic and
therapeutic guidelines // J. Am. Acad. Nurse Pract. — 2002. — Vol. 58, N
12. — P. 1063–1066.
271. Hextall E. Estrogens in the function uretral tract // Maturitas. — 2000. —
Vol. 36. — P. 83–92.
272. Urinary incontinence and depression in middle-age United States
women / I. Nygaard, C. Turvey, E. Crischilles et al. // Obstet. Gynecol. —
2003. — Vol. 101, N 1. — P. 149–156.
273. Impaired folliculogenesis and ovulation in older reproductive aged
women / N. Santoro, B. Isaac, G. Neal-Perry et al. // J. Clin. Endocrinol.
Metab. — 2003. — Vol. 88, N 11. — P. 5502–5509.
274. Influence of dietary and genetic factors on metabolic status in obese
and lean postmenopausal women / A. Milewicz, M. Demissie, K. Zatonska et
al. // Gynecol. Endorcinol. — 2003. — Vol. 17, N 4. — P. 333–338.
275. Ethnic variation in bone density in premenopausal and early
perimenopausal women: effects of anthropometric and lifestyle factors / J.S.
Finkelstein, M.L. Lee, M. Sowers et al. // J. Clin. Endocrinol. Metab. — 2002. —
Vol. 87, N 7. — P. 3057–3067.
276. Menopausal status and sleep-disordered breathing in the Wisconsin
Sleep Cohort Study / T. Young, L. Finn, D. Austin et al. // Am. J. Respir.
Crit. Care Med. — 2003. — Vol. 167. — P. 1181–1185.
277. Hay A.G., Bancroft J., Johnstone E.C. Affective symptoms in women
attending a menopause clinic // Br. J. Psychiatry. — 1994. — Vol. 164. —
P. 513.
278. Reid G. Probiotics for urogenital health // Nutr. Clin. Care. — 2002. —
Vol. 5, N 1. — P. 3–5.
279. Hernandez C.J., Beaupre G.S., Carter D.R. A theoretical analysis of the
changes in basic multicellular unit activity at menopausae? // Maturitas. —
Vol. 32, N 4. — P. 357–363.
280. Col N.F., Pauker S.G. The discrepancy between observational studies
and randomized trials of menopausal hormone therapy: did expectations shape
experience? // Ann. Intern. Med. — 2003. — Vol. 139. — P. 923–929.
281. Hersh A.L., Stefanick M.L., Stafferd R.S. National use of postmenopausal
hormone therapy: annual trends and response to recent evidence // JAMA. —
2004. — Vol. 291. — P. 47–53.
282. Changes in the use of postmenopausal hormone therapy after the
publication of clinical trial results / J.S. Haas, C.P. Kaplan, E.P. Gerstenberger
et al. // Ann. Intren. Med. — 2004. — Vol. 140. — P. 184–188.
283. Benefits and harms associated with hormone replacement therapy:
clinical decision analysis / C. Minelli, K.R. Abrams, A.J. Sutton et al. // BMJ. —
2004. — Vol. 328. — P. 371.
284. Prospective study of postmenopausal hormone use and newly
diagnosed asthma and chronic obstructive pulmonary disease / R.G. Barr,
C.C. Wentowski, F. Grodstein et al. // Arch. Intern. Med. — 2004. — Vol.
164. — P. 379–386.
285. Estrogen plus progestine and colorectal cancer in postmenopausal
women / R.T. Chlebowski, J. Wactawski-Wende, C. Ritenbaugh et al. //
N. Engl. J. Med. — 2004. — Vol. 350. — P. 991–1004.
286. Nelson H.D. Postmenopausal estrogen for treatment of hot flashes:
clinical applications // JAMA. — 2004. — Vol. 291. — P. 1621–1625.
287. Nelson H.D. Commonly used types of postmenopausal estrogen for
treatment of hot flashes: Scientific review // Ibid. — P. 1610–1620.
288. Effects of conjugated equine estrogen in postmenopausal women
with hysterectomy: the Women’s Health Initiative randomized controlled
trial / G.L. Anderson, M. Limacher, A.R. Assaf et al. // Ibid. — N 14. —
P. 1701–1712.
289. Bush T.A., Castellucci D.T., Phillips C. Exploring women’s beliefs
regarding urinary incontinence // Urol. Nurs. — 2001. — Vol. 21, N 3. —
P. 201–210.
290. Biofeedback and electrical stimulation therapy for treating urinary
incontinence and voiding / S. Abdelghany, J. Hughes, J. Lammers et al. //
Ibid. — N 6. — P. 401–505, 410.
291. Depressive symptoms in women with urinary incontinence: a
prospective study / P. Meade-D’Alisera, T. Merriweather, M. Wentland et
al. // Ibid. — P. 397–399.
292. Broome B.A. Psychometric analysis of the Broome Pelvic Muscle
Self-Efficacy Scale in African-American women with incontinence // Ibid. —
N 4. — P. 283–288.
293. Female stress urinary incontinence facts / L. Butler, B. DowneWamboldt, S. Marsh et al. // Ibid. — N 3. — P. 134.
294. Criner J.A. Urinary incontinence in vulnerable populations: female
soldiers // Ibid. — N 2. — P. 120–124.
295. Kincade J.E., Peckous B.K., Busby-Whitehead J. A pilot study
to determine predictors of behavioral treatment completion for urinary
incontinence // Ibid. — N 1. — P. 39–44.
296. Bother arising from urinary frequency in women / M.P. FitzeGerald,
N. Butler, S. Shott et al. // Neurourol. Urodyn. — 2002. — Vol. 21, N 1. —
P. 36–40.
297. FitzeGerald M.P., Brubaker L. Urinary incontinence symptom scores
and urodynamic diagnoses // Ibid. — P. 30–35.
298. Detrusor biopsy as a potential clinical tool / M.A. Mastropietro, W.
Geary, E. Fuller et al. // Int. Urogynecol. J. Pelvic Floor Dysfunct. — 2001. —
Vol. 12, N 6. — P. 355–360.
299. Nguyen J.K., Glowacki C.A., Bhatia N.N. Survey of voiding dysfunction
and urinary retention after anti-incontinence procedures // Obstet. Gynecol. —
2001. — Vol. 98, N 6. — P. 1011–1017.
300. Risk of new-oset urinary incontinence after forceps and delivery in
primiparous women / L.A. Arya, N.D. Jackson, D.L. Myers et al. // Am. J.
Obstet. Gynecol. — 2001. — Vol. 185, N 6. — P. 1318–1324.
301. Nguyen J.K., Bhatia N.N. Resolution of motor urge incontinence after
surgical repair of pelvic organ prolapse // Urology. — 2001. — Vol. 166, N 6. —
P. 2263–2266.
302. Classification and pharmacology of progestins / A.E. Schindler, C.
Campagnoli, R. Druckmann et al. // Maturitas. — 2003. — Vol. 46, suppl. 1 —
P. 7–16.
303. Metabolic and vascular effect of progestins in postmenopause / G.M.C.
Rosano, C. Vitale, A. Silvestri et al. // Ibid. — P. 17–29.
304. Differential affects of progestins on the circulating IGF-I system /
C. Campagnoli, C. Abba, S. Ambroggio et al. // Ibid — P. 39–44.
305. Pasqualini J.R. Differential affects of progestins on the breast tissue
enzymes // Ibid. — P. 45–54.
306. Gruber C.J., Huber J.C. Differential affects of progestins on the brain //
Ibid — P. 71–75.
307. Nelson H.D. Estrogen levels in women // J. Clin. Endocrinol. Metab. — 2001. —
Vol. 86, N 6. — P. 2562–2568.
308. Schnedler A.E., Palasious S.B. Overview on the effects of estrogen and
progestins // Maturitas. — 2003. — Vol. 46, suppl. 1. — P. 61–68.
309. De Groat W.C. Nervous control of the urinary bladder of the cat //
Brain Res. — 1975. — Vol. 87. — P. 201–211.
310. The standardization of terminology of lower urinary tract function:
Report from the standardization sub-committee of the International Continence
Society / P. Abram, L. Cardozo, M. Fall et al. // Neurourol. Urodyn. — 2003. —
Vol. 21. — P. 167–178.
311. Steers W.D. Overactive Bladder (OAB): What we thought we knew
and what we know today // Eur. Urol. Suppl. — 2002. — Vol. 1, N 4. —
P. 3–10.
312. Stenberg A., Heimer G., Ulmsten U. The prevalence of urogenital
symptoms in postmenopausal women // Maturitas. — 1995. — Vol. 22, suppl. —
P. 17–20.
313. Ulmsten U. On urogenital ageing // Ibid. — 1994 — Vol. 40, suppl 3. —
P. 163–169.
314. Quality of life of persons with urinary incontinence: development of a
new measure / T.H. Wagner, D.L. Patrick, T.G. Bavendam et al. // Urology. —
1996. — Vol. 47, N 1. — P. 67–72.
315. Steers W., Lee K.S. Depression and incontinence // World J. Urol. —
2001. — Nov. — Vol. 19, suppl. 5. — P. 351–357.
316. A systematic review of estrogens for recurrent urinary tract infections:
third report of the hormones and urogenital therapy (HUT) committee /
L. Cardozo, G. Lose, D. Mc Clish et al. // Int. Urogynecol. J. Pelvic Floor
Dysfunct. — 2001. — Vol. 12. — P. 15–20.